Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Background. Omalizumab has been introduced for treatment of severe steroid dependent asthma in Bulgaria since 2009. We analyzed its effectiveness in a patient population eligible for reimbursement according the National Health Insurance Fund criteria.Methods. We reviewed the records of all asthmatics put on omlizumab treatment through an established selection process in one of the 2 centers in the country. The variables included demographic data, disease and smoking history, spirometry, total IgE, blood eosinophils, success of treatment as judged by patients and doctors, discontinuation of systemic steroids, adverse events.Results. A total of 76 patients (52 women, 68%) on omalizumab had data from at least two visits 6 months apart. All were atopic with total IgE ranging from 81 to 1466 (median 302) IU/mL. Baseline FEV1 % predicted was 47.7%±5.8% [mean±s.e.m.] and blood eosinophils 410±48 cells/mcL. 13 patients (17%) discontinued treatment: 9 patients not experiencing subjective improvement, 3 patients having no effect as judged by their doctors, and 1 patient because of anaphylaxis. Binary logistic regression associated success of treatment positively with age and negatively with preceding asthma duration and pack years of smoking: odds ratio for success in relation to age was 1.065, 95% CI [1.004-1.130], P=0.04; to asthma duration 0.951 [0.904-1.001], P=0.05; to pack years 0.927 [0.864 -0.995], P=0.04.Conclusions. The majority (83%) of consecutive severe asthmatics on omalizumab in real-life patient population met the goals of treatment, with age as positive predictor of success; asthma duration and smoking were associated with the odds of failure.


Rating:

Share or cite this content

Citations should be made in the following way:
Tanya Kralimarkova (Sofia, Bulgaria), Tanya Kralimarkova, Maria Staevska, Tsvetelina Lazarova, Diana Hristova, Vasil Dimitrov, Todor Popov. Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting. Eur Respir J 2015; 46: Suppl. 59, 1018

Member's Comments

No comment yet.

Related content which might interest you: Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Study of antioxidant use in patients with asthma exacerbations Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 The parameters that may affect inhalation therapy success in elderly COPD and asthma patients Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Use of beta-agonist therapy prior to hospital attendance for severe exacerbations of asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations Source: International Congress 2015 – Management of asthma and COPD in primary care Year: 2015 Evaluation of methotrexate in the treatment of severe asthma Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Metrics of salbutamol use as predictors of future adverse outcomes in asthma Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Finding asthmatics suitable for omalizumab therapy in a district hospital Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Pharmacological strategies for self-management of asthma exacerbations Source: Eur Respir J 2006; 28: 182-199 Year: 2006 Long-term management of persistent asthma in adults Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=376 Year: 2003 Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015